Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma

Blood Transfusion Centre of Slovenia30 enrolled

Overview

Interventional study of modulation of immune response in patients with pancreatic tubular adenocarcinoma after resection and gemcitabine treatment. When included, patients are pre-treated with moderate doses of cyclophosphamide. Then infusions of allogeneic mononuclear cells are given.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pancreatic Tubular Adenocarcinoma

Interventions

MISBIOLOGICAL

Cell infusion

Eligibility

Sex: ALLMin age: 30 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ECOG performance status 0-2 at the time of inclusion * Following R0 or R1 pancreatic tubular adenocarcinoma resection and adjuvant gemcitabine treatment Exclusion Criteria: * Pregnancy * Less than 3 mths expected survival * Serious comorbidity * Age above 70 yrs

Locations (1)

University Medical Centre Ljubljana, Department for Gastroenterolgy

Ljubljana, Ljubljana, Slovenia

RECRUITING

Outcomes

Primary Outcomes

PROGRESSION FREE SURVIVAL

Time frame: 1 YEAR

Central Contacts

Borut Stabuc, MD PhD

CONTACT

+38615222210 borut.stabuc@kclj.si

Lojze Smid, MD

CONTACT

lojze.smid.jr@mf.uni-lj.si

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.